Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Andrew J AhmannMatthew CapehornGuillaume CharpentierFrancesco DottaElena HenkelIldiko LingvayAnders G HolstMiriam P AnnettVanita R ArodaPublished in: Diabetes care (2017)
Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles. These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.
Keyphrases
- body weight
- glycemic control
- open label
- type diabetes
- clinical trial
- estrogen receptor
- randomized controlled trial
- squamous cell carcinoma
- breast cancer cells
- radiation therapy
- study protocol
- metabolic syndrome
- weight loss
- phase ii study
- replacement therapy
- preterm birth
- gestational age
- rectal cancer
- locally advanced